Shares of Zimmer Biomet Holdings Inc (NYSE:ZBH) ended Friday session in red amid volatile trading. The shares closed down -4.71 points or -3.62% at $125.29 with 200.01 million shares getting traded. Post opening the session at $128.97 the shares hit an intraday low of $125.28 and an intraday high of $129.04 and the price vacillated in this range throughout the day. The company has a market cap of $24.15 billion and the numbers of outstanding shares have been calculated to be 200.01 million shares.
Zimmer Biomet Holdings Inc (ZBH) on Sept. 7, 2016 announced that its Warsaw, Indiana-based headquarters will be wholly powered by renewable, green energy, in compliance with the U.S. Environmental Protection Agency’s (EPA) Green Power Partnership program. Green power is zero-emissions electricity that is generated from environmentally preferable renewable resources, such as wind, solar, geothermal, biogas, eligible biomass, and low-impact hydro. Zimmer Biomet’s headquarters building will receive green power from Northern Indiana Public Service Company (NIPSCO), an approved provider of green power for the EPA’s Green Power Program, which allows homes and businesses to designate a portion, or all, of their monthly electric usage to be attributable to electricity generated by renewable energy sources.
“We are proud to partner with the EPA and NIPSCO to lead the green power revolution in Indiana by converting 100 percent of our headquarters’ power consumption to renewable energy sources,” said Robin T. Barney, Senior Vice President, Global Operations and Logistics. “Sustainably and responsibly sourcing our electric power is a critical milestone in advancing Zimmer Biomet’s longstanding commitment to sustainability, and we hope our efforts inspire local area businesses and residents to join the EPA’s Green Power Program to collectively reduce our region’s environmental footprint.”
Shares of Juno Therapeutics Inc (NASDAQ:JUNO) ended Friday session in red amid volatile trading. The shares closed down -1.73 points or -5.82% at $28.02 with 105.78 million shares getting traded. Post opening the session at $29.33 the shares hit an intraday low of $28.01 and an intraday high of $29.45 and the price vacillated in this range throughout the day. The company has a market cap of $2.79 billion and the numbers of outstanding shares have been calculated to be 105.78 million shares.
Juno Therapeutics Inc (JUNO) engages in developing cell-based cancer immunotherapies. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells. Its clinical stage CD19 product candidates include JCAR015 that is in Phase II clinical trials for adult patients with relapsed/refractory B cell acute lymphoblastic leukemia (r/r ALL); JCAR017, which is in Phase I/II trials for pediatric patients with r/r ALL; and JCAR014 that is in Phase I/II trials to treat various B cell malignancies in patients relapsed or refractory to standard therapies.